Omnicell Free Cash Flow 2010-2024 | OMCL
Omnicell free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Omnicell Annual Free Cash Flow | |
|---|---|
| 2024 | 151.26 |
| 2023 | 139.62 |
| 2022 | 30.25 |
| 2021 | 202.84 |
| 2020 | 163.03 |
| 2019 | 129.11 |
| 2018 | 80.27 |
| 2017 | 9.49 |
| 2016 | 36.46 |
| 2015 | 30.94 |
| 2014 | 53.24 |
| 2013 | 42.93 |
| 2012 | 24.36 |
| 2011 | 22.56 |
| 2010 | 13.71 |
| 2009 | 42.63 |
| Omnicell Quarterly Free Cash Flow | |
|---|---|
| 2024-12-31 | 151.26 |
| 2024-09-30 | 104.03 |
| 2024-06-30 | 90.15 |
| 2024-03-31 | 41.00 |
| 2023-12-31 | 139.62 |
| 2023-09-30 | 110.28 |
| 2023-06-30 | 63.90 |
| 2023-03-31 | 2.63 |
| 2022-12-31 | 30.25 |
| 2022-09-30 | -38.23 |
| 2022-06-30 | -46.65 |
| 2022-03-31 | -27.49 |
| 2021-12-31 | 202.84 |
| 2021-09-30 | 154.29 |
| 2021-06-30 | 118.12 |
| 2021-03-31 | 52.33 |
| 2020-12-31 | 163.03 |
| 2020-09-30 | 92.16 |
| 2020-06-30 | 59.52 |
| 2020-03-31 | 22.06 |
| 2019-12-31 | 129.11 |
| 2019-09-30 | 97.56 |
| 2019-06-30 | 44.39 |
| 2019-03-31 | 21.52 |
| 2018-12-31 | 80.27 |
| 2018-09-30 | 37.26 |
| 2018-06-30 | 25.74 |
| 2018-03-31 | 9.59 |
| 2017-12-31 | 9.49 |
| 2017-09-30 | 11.27 |
| 2017-06-30 | 32.43 |
| 2017-03-31 | 25.73 |
| 2016-12-31 | 36.46 |
| 2016-09-30 | 16.03 |
| 2016-06-30 | 10.95 |
| 2016-03-31 | 17.75 |
| 2015-12-31 | 30.94 |
| 2015-09-30 | -0.15 |
| 2015-06-30 | 6.43 |
| 2015-03-31 | 10.27 |
| 2014-12-31 | 53.24 |
| 2014-09-30 | 24.16 |
| 2014-06-30 | 18.09 |
| 2014-03-31 | -1.43 |
| 2013-12-31 | 42.93 |
| 2013-09-30 | 32.92 |
| 2013-06-30 | 15.52 |
| 2013-03-31 | 0.83 |
| 2012-12-31 | 24.36 |
| 2012-09-30 | 17.92 |
| 2012-06-30 | 14.67 |
| 2012-03-31 | 5.85 |
| 2011-12-31 | 22.56 |
| 2011-09-30 | 7.82 |
| 2011-06-30 | 2.50 |
| 2011-03-31 | 0.69 |
| 2010-12-31 | 13.71 |
| 2010-09-30 | 5.81 |
| 2010-06-30 | 10.21 |
| 2010-03-31 | 7.05 |
| 2009-12-31 | 42.63 |
| 2009-09-30 | 22.25 |
| 2009-06-30 | 4.30 |
| 2009-03-31 | -3.27 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.460B | $1.112B |
| Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs. The company also adheres to regulatory compliances and addresses issues related to population health. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $38.476B | 53.14 |
| Tempus AI (TEM) | United States | $9.826B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $9.069B | 145.79 |
| Inspire Medical Systems (INSP) | United States | $4.756B | 92.38 |
| IRhythm Technologies (IRTC) | United States | $4.186B | 0.00 |
| Privia Health (PRVA) | United States | $2.829B | 212.00 |
| Enovis (ENOV) | United States | $2.016B | 12.47 |
| Schrodinger (SDGR) | United States | $1.847B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.706B | 0.00 |
| Phreesia (PHR) | United States | $1.512B | 0.00 |
| Azenta (AZTA) | United States | $1.232B | 57.36 |
| 10x Genomics (TXG) | United States | $1.031B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.634B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.566B | 0.00 |
| Talkspace (TALK) | United States | $0.537B | 319.00 |
| Veradigm (MDRX) | United States | $0.476B | 0.00 |
| Standard BioTools (LAB) | United States | $0.456B | 0.00 |
| TruBridge (TBRG) | United States | $0.392B | 0.00 |
| Claritev (CTEV) | United States | $0.362B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.294B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.208B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.202B | 0.00 |
| Pulmonx (LUNG) | United States | $0.152B | 0.00 |
| American Well (AMWL) | United States | $0.116B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.097B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.085B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.081B | 0.00 |
| CareCloud (CCLD) | United States | $0.080B | 3.43 |
| 111 (YI) | China | $0.072B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.063B | 0.00 |
| HeartBeam (BEAT) | United States | $0.061B | 0.00 |
| Outset Medical (OM) | United States | $0.044B | 0.00 |
| Zepp Health (ZEPP) | China | $0.039B | 0.00 |
| Zhongchao (ZCMD) | China | $0.029B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.021B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.017B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.016B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.013B | 0.00 |
| Precipio (PRPO) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.009B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |